PUBLISHER: Grand View Research | PRODUCT CODE: 1908538
PUBLISHER: Grand View Research | PRODUCT CODE: 1908538
The global bioplastics in medical devices market size was estimated at USD 2.11 billion in 2024 and is projected to reach USD 5.06 billion by 2033, growing at a CAGR of 10.3% from 2025 to 2033. The rising demand for minimally invasive procedures is driving the use of lightweight, flexible, and patient-friendly components made from bioplastics.
Hospitals prefer these materials because they support safer device designs while reducing waste handling costs. Demand for bioplastics in medical devices is shifting from niche research to scaled clinical use. Temporary implants, resorbable sutures, and single-use disposables are increasingly specified for their lifecycle benefits and lower embedded carbon. Manufacturers are investing in material qualification and supply-chain scale-up to meet rising procurement from hospitals and medtech firms. This movement is supported by expanding market forecasts and sector-specific analyses.
Drivers, Opportunities & Restraints
Regulators and large hospital systems are tightening requirements around single-use plastic waste and carbon accounting. Buyers now favor materials that enable end-of-life options such as industrial composting or controlled biodegradation, where clinically appropriate. These policies and procurement signals push device OEMs to validate bioplastic alternatives and to demonstrate comparable safety and sterilization performance. Technical literature also documents growing R&D into medical-grade biopolymers.
Bioplastics provide OEMs a clear path to product differentiation in categories where temporary functionality is required. Resorbable orthopedic pins, scaffolds for tissue regeneration, and biodegradable delivery carriers reduce the need for secondary procedures and can lower the total cost of care. Early movers who close gaps in cost, processing, and regulatory dossiers can capture premium tender positions with health systems pursuing sustainability targets. Market projections indicate significant upside potential for focused medical bioplastics segments.
Clinical adoption is constrained by sterilization compatibility, controlled degradation rates, and long-term biocompatibility data requirements. Recent studies have also raised questions about additive toxicity and microfragment behavior for some starch-based and biodegradable formulations. At the same time, feedstock and scale limitations keep unit costs higher than those of commodity polymers. These combined technical and economic barriers slow procurement at scale until validated, lower-cost supply chains and clearer safety data emerge.
Global Bioplastics In Medical Devices Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global bioplastics in medical devices market report on the basis of material, application, and region: